IPCALAB Intraday Analysis...

IPCALAB Share Price

Open 511.00 Change Price %
High 520.00 1 Day -21.25 -4.17
Low 483.95 1 Week -53.25 -9.83
Close 488.70 1 Month -105.10 -17.70
Volume 62214 1 Year 47.65 10.80
52 Week High 657.60
52 Week Low 404.00
IPCALAB Important Levels
Resistance 2 522.12
Resistance 1 508.35
Pivot 497.55
Support 1 469.05
Support 2 455.28
NSE INDIA Most Active Stocks
SUZLON 18.85 -4.56%
JPASSOCIAT 9.30 -9.27%
RCOM 25.90 -7.50%
SINTEX 104.10 -0.48%
GMRINFRA 14.55 -8.49%
SOUTHBANK 25.25 -1.37%
TATAMOTORS 469.55 4.23%
HDIL 83.85 1.08%
IBREALEST 159.80 -3.76%
JINDALSTEL 111.10 2.73%
More..
NSE INDIA Top Gainers Stocks
KSERASERA 0.15 50.00%
VISESHINFO 0.15 50.00%
KESARENT 100.80 20.00%
ELECTHERM 237.75 19.98%
XCHANGING 60.60 12.33%
SPCENET 0.55 10.00%
FMNL 77.85 9.96%
INDOTHAI 33.95 9.87%
MAITHANALL 420.10 9.13%
GENUSPAPER 5.40 9.09%
More..
NSE INDIA Top Losers Stocks
RASOYPR 0.15 -25.00%
AUSTRAL 0.25 -16.67%
ORTEL 75.70 -15.13%
SPYL 0.30 -14.29%
GTOFFSHORE 11.95 -13.09%
SITASHREE 5.15 -12.71%
SATHAISPAT 41.15 -11.51%
NICCO 0.40 -11.11%
MUKANDLTD 66.95 -10.73%
LSIL 1.75 -10.26%
More..

IPCA Laboratories Limited (NSE: IPCALAB)

IPCALAB Technical Analysis 5
As on 24th May 2017 IPCALAB Share Price closed @ 488.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 550.36 & Strong Sell for SHORT-TERM with Stoploss of 574.65 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPCALAB Target for May
1st Target up-side 640.34
2nd Target up-side 669.99
3rd Target up-side 699.63
1st Target down-side 555.76
2nd Target down-side 526.11
3rd Target down-side 496.47
IPCALAB Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is Below 30 Over Sold
MFI (14) MFI is 51.16 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Short Sell 563.96
10 Day Avg Volume Traded -3.26 % Less then 10 Day Average Volume
IPCALAB Other Details
Segment EQ
Market Capital 34699423744.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipcalabs.com
IPCALAB Address
IPCALAB
142 AB, Kandivli Industrial Estate
Kandivli (West)
Mumbai, 400067
India
Phone: 91 22 6647 4747
Fax: 91 22 2868 6954
Interactive Technical Analysis Chart IPCA Laboratories Limited ( IPCALAB NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on IPCA Laboratories Limited
IPCALAB Business Profile
Ipca Labs is in the Pharmaceuticals - Bulk Drugs and Formulation sector. Ipca Laboratories (IPCA), a recognized trading house, exports to over 108 countries. Over 60% of its turnover comes from specialty formulations such as anti-malarials, anti-emetics, anti-hypertensives, antibiotics and other drugs. The balance comes from bulk drugs, drug intermediates, generic formulations, hospital products, ..etc. The company works out of its various divisions namely general pharma division, Intima division, Activa division, 3C division, Innova division and Hycare division. It is the largest Indian manufacturer of anti-malarial bulk drug chloroquine phosphate. The formulations manufacturing unit of the company in Athal, Silvassa is being expanded and upgraded to meet the growing formulations export business. The company exports formulations as well as APIs to several Asian countries. The company markets branded formulations to Sri Lanka, Myanmar and Vietnam. During 2004-2005, the company introduced 15 new products in the domestic market. New products introduced during the last three financial years now constitute nearly 24% of its domestic formulations sales. The company is setting up new formulations manufacturing unit at the special economic zone (SEZ) Indore. IPCA currently has five wholly-owned overseas subsidiary companies after amalgamation of the wholly-owned subsidiary Innotech Pharma with the company. The company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same. The current market capitalisation stands at Rs 8,614.35 crore.The company has reported a consolidated sales of Rs 1292.64 crore and a Net Profit of Rs 95.07 crore for the quarter ended Mar 2009. The company management includes Premchand Godha - Chairman & Managing Director, Ajit Kumar Jain - Joint Managing Director, Pranay Godha - Executive Director, Prashant Godha - Executive Director, Madhukar R Chandurkar - Director, Babulal Jain - Director, V V Subba Rao - Director, Anand T Kusre - Director, Dev Parkash Yadava - Director, Ramakanta Panda - Director. It is listed on the BSE with a BSE Code of 524494 and the NSE with an NSE Code of IPCALAB. Its Registered office is at 48, Kandivli Industrial Estate, Kandivli (West), Mumbai,Maharashtra - 400067.